Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic 1

3220 - ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)


08 Sep 2017


NSCLC, metastatic 1


Cytotoxic Therapy;  Immunotherapy;  Non-Small Cell Lung Cancer


Daniel Morgensztern


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


D. Morgensztern1, T.J. Ong2, M. Cobo Dols3, S. Ponce Aix4, P.E. Postmus5, C. Lewanski6, J. Bennouna7, J.R. Fischer8, O.J. Vidal9, D.J. Stewart10, G. Fasola11, A. Ardizoni12, J. Weaver2, M. Wolfsteiner13, D. Talbot14, R. Govindan1

Author affiliations

  • 1 Division Of Oncology, Washington University School of Medicine, 63110 - St Louis/US
  • 2 Medical Oncology, Celgene Corporation, Summit/US
  • 3 Medical Oncology, Hospital Regional Universitario Carlos Haya – Hospital General, Malaga/ES
  • 4 Oncology, Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIO,, Madrid/ES
  • 5 Medical Oncology, Clatterbridge Cancer Centre, Liverpool/GB
  • 6 Medical Oncology, Charing Cross Hospital, London/GB
  • 7 Thoracic Oncology, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes Atlantique, Nantes, Loire-Atlantique/FR
  • 8 Medical Oncology, Lungenklinik Löwenstein, Löwenstein, Baden-Württemberg/DE
  • 9 Oncology, Hospital Universitari i Politècnic La Fe, Valencia/ES
  • 10 Medicine, Ottawa Hospital, Ottawa/CA
  • 11 Oncology, University Hospital Santa Maria della misericordia, Udine/IT
  • 12 Oncology, Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna/IT
  • 13 Oncology, PRA Health Sciences, Lenexa/US
  • 14 Oncology, Oxford University Hospitals Trust, Oxford/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3220


Therapy selection for previously treated patients with advanced NSCLC is evolving. ABOUND.2L+ evaluated safety and efficacy of nab-P monotherapy, nab-P + the epigenetic modifying agent CC-486, and nab-P + the PD-L1 inhibitor durvalumab.


Patients with advanced nonsquamous NSCLC and ≤ 1 prior chemotherapy were randomized to nab-P 100 mg/m2 on days 8 and 15 + CC-486 200 mg QD on days 1-14 or nab-P alone 100 mg/m2 on days 1 and 8, both administered q3w. The protocol was amended to include a nab-P + durvalumab arm (nab-P 100 mg/m2 on days 1 and 8 + durvalumab 1125 mg on day 15, q3w), which began enrolling after the other arms had completed enrollment and allowed the inclusion of patients with squamous histology or prior immunotherapy treatment. For all patients, treatment continued until unacceptable toxicity or tumor progression.


A total of 240 patients were enrolled. In the nab-P + CC-486 and nab-P arms, the median number of cycles was 4 and the median cumulative dose of nab-P was 600 and 800 mg/m2, respectively. Grade 3 or 4 (G3/4) treatment-emergent adverse events (AEs) were 59.5% and 54.4%, respectively. The most frequent hematologic G3/4 AEs were neutropenia (16.5% vs 10.1%) and anemia (1.3% vs 7.6%). G3/4 peripheral neuropathy occurred in 2.5% vs 7.6% of patients (nab-P + CC-486 vs nab-P). Adding CC-486 to nab-P did not result in improvements in PFS, OS, ORR, or DCR (Table). Preliminary data for 79 patients in the nab-P + durvalumab arm showed a median PFS of 4.4 months, median OS not estimable, a 20% ORR, and a 71% DCR. No new safety signals were identified.



nab-P + CC-486 n = 81nab-P n = 80
Primary endpoint
Median PFS, months3.24.2
HR (95% CI) 1.3 (0.9 - 2.0)
Secondary endpoints
Median OS, months8.412.7
HR (95% CI) 1.4 (0.88 - 2.31)
ORR, n (%)a11 (13.6)11 (13.8)
Response rate ratio (95% CI) 0.99 (0.45 - 2.15)
Complete response Partial response Stable disease Progressive disease DCR (≥ stable disease)0 11 (13.6) 41 (50.6) 22 (27.2) 52 (64.2)0 11 (13.8) 43 (53.8) 19 (23.8) 54 (67.5)

DCR, disease control rate; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.


Response rate was based on the intent-to-treat population; however, 14 patients did not have a response assessment.


Single-agent nab-P is promising in previously treated nonsquamous NSCLC; addition of CC-486 did not appear to benefit patients clinically. Updated data for the ongoing durvalumab combination arm of the study will be presented. NCT02250326.

Clinical trial identification


Legal entity responsible for the study



Celgene Corporation


D. Morgensztern: Consultant: Celgene, Abbvie and Bristol-Myers Squibb. T.J. Ong, J. Weaver: Full-time employee: Celgene Corporation. P.E. Postmus: Advisory Board: Advisory board Celgene, AstraZeneca, Roche, BMS, BI, Janssen, MSD, Clovis. C. Lewanski: Advisory Board Member: Eli Lilly. J. Bennouna: Advisory Board: Roche, Boehringer-Ingelheim, Astra-Zeneca, BMS; Honoraria: Roche, Boehringer-Ingelheim, Astra-Zeneca, BMS. J.R. Fischer: Employment: Klinik Löwenstein; Advisory Board: Astra Zeneca, BMS, Celgene, Roche, MSD, Boehringer; Consultant: Celgene; Speaker’s Bureau: Astra Zeneca, Celgene, Roche, BMS; Honoraria: Astra Zeneca, BMS, Celgene, Roche, MSD, Boehringer. D.J. Stewart: Grants/Research Support Recipient: Clinical trials support: Celgene, Boehringer Ingelheim, Astra Zeneca, Novartis, Bristol-Myers Squibb; Advisory Board: Roche Canada; Pfizer Canada; Boehringer Ingleheim Canada, Amgen, Novartis Canada. A. Ardizoni: Honoraria from Eli-Lilly, BMS, MSD, Boehringer. M. Wolfsteiner: Employment: FTE at PRA Health Sciences, contracted for Celgene (current). D. Talbot: Honoraria - Pfizer; Pierre Fabre Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Novartis; Pfizer; Roche Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Lilly; Merck Sharp & Dohme; Novartis. R. Govindan: Honoraria - Boehringer Ingelheim Consulting or Advisory Role - Abbvie; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Helsinn Therapeutics; Novartis Research Funding - Abbvie (Inst); Bayer (Inst); GlaxoSmithKline (Inst); MethylGene (Inst) Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Merck All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.